Good Samaritan and Palliative Care to host Family Fun Fair
The event is to be held in honor of members of the community who have gone through tremendous loss. The event will take place on June 7 from 11 a.m. to 8 p.m. at Highland Woods Park. The event will offer a slew of activities for families including:
Inflatables and bounce houses
· Face painting
· Carnival games
· Food trucks
· Dunk tank
· Contests and prizes
· A cornhole tournament
Wristbands for children will be $15 and will allow access to all the inflatables and carnival games. Proceeds from the event will go to benefit the Good Grief Support Group and Camp Memiki, a grief camp for children.
Makenzie Barrett, RN, Nurse Manager for Hospice and Palliative Care at Good Samaritan, said the event is a chance to celebrate life while raising awareness.
'Grief can be an isolating experience,' Barrett said. 'Our goal is to let people know they are not alone, and that support is available. The Family Fun Fair is a joyful way to connect with our community and spread that message.'
The Good Samaritan Grief Support Group meets every other Thursday at 6 p.m. EST in the Cancer Pavilion located at 520 South Seventh Street and is open to anyone dealing with the loss of a loved one. After losing her daughter unexpectedly in 2022, people like Vincennes resident Tami Kinman have used the group to deal with the immense feelings of grief.
'I thought I knew grief,' Tami shared. 'But nothing prepared me for the overwhelming pain of losing my daughter. It completely broke me.'
Now, more than a year later, Tami has said how much the group helped save her from that grief.
'The people in that room knew what it felt like to be broken,' she said. 'They helped me find tools to cope. Honestly, I believe this group helped save my life.'
To learn more about the event or to support Good Samaritan's grief services, you can visit this link. Individuals seeking support can also call Hospice at 812-885-8035.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 days ago
- Medscape
Lorazepam for Cancer Patients With Delirium? What to Know
Lorazepam and other benzodiazepines are typically avoided when managing end-of-life agitated delirium in patients with cancer because these drugs can precipitate, even worsen, delirium. But a new multicenter trial found that patients with advanced cancer and delirium experienced greater reductions in agitation and restlessness at the end-of-life when given lorazepam compared with the more frequently used haloperidol. 'Lorazepam-based regimens were found to be more efficacious than haloperidol alone or placebo in reducing agitation and restlessness in patients who were admitted to the palliative care unit with persistent agitated delirium,' said study lead author David Hui, MD, professor of palliative, rehabilitation and integrative medicine at the University of Texas MD Anderson Cancer Center, Houston. Delirium — a serious change in mental abilities that leads to confused thinking and a lack of awareness — affects more than 90% of patients in their last days or weeks of life, with up to 70% of these patients developing restlessness, agitation, or both. Although a common issue at the end-of-life, delirium often goes underrecognized and there are no guidelines for treating it. The current analysis found that patients with advanced cancer and delirium who received lorazepam or a combination of haloperidol and lorazepam had lower Richmond Agitation-Sedation Scale (RASS) scores than those given haloperidol alone and required rescue medications less frequently to control breakthrough restlessness or agitation. Although lorazepam-based regimens led to better symptom control in this patient population, the findings don't necessarily mean that all should receive a benzodiazepine, Hui told Medscape Medical News . Managing delirium requires achieving a delicate balance between lowering the symptoms and preserving patients' alertness. These final days are 'one of the most precious times for families to interact with the patients,' Hui explained, and these new data can help oncologists and families 'develop a personalized approach to the best management of delirium for a specific patient.' Treating End-of-Life Delirium: The Data Hui and his colleagues conducted the current study to better understand the risks and benefits of using neuroleptic or benzodiazepine agents to control restlessness and agitation intensity in patients with cancer and delirium receiving palliative care. The study included patients aged 18 years or older with an advanced cancer diagnosis who had been admitted to an acute palliative care unit in Taiwan or the US from July 2019 to June 2023. Patients had delirium, a history of hyperactivity, and were taking standard-dose haloperidol (< 8 mg/d) or required 4 mg/d or more of rescue haloperidol for agitation in the past 24 hours. Overall, 72 patients were randomized to one of four groups — scheduled haloperidol with dose escalation (12 mg/d), lorazepam alone, lorazepam plus haloperidol, and placebo on restlessness and agitation intensity in the advanced cancer patients. 'For ethical reasons,' the authors said, the placebo group received lorazepam as a rescue medication. The primary outcome was change in RASS score during the first 24 hours of treatment, though patients were followed for 30 days after medication administration. RASS scores spanned a 10-point scale, ranging from -5 to 4, with -5 representing deeply sedated or unarousable and 4 being combative. At enrollment, all patients started taking 2 mg of haloperidol intravenously every 6 hours and 2 mg intravenously every hour as needed. Patients were monitored until they reached an RASS score of at least 1, at which time researchers switched to the blinded phase in which patients were randomized to their scheduled medication every 4 hours, plus a rescue medication every hour as needed. RASS scores were initially similar in the four groups: 1.7 for haloperidol, 1.6 for lorazepam alone, 1.3 for lorazepam plus haloperidol, and 1.6 for placebo. Within the first hour, RASS scores decreased significantly in all four groups, with the lowest scores in the two lorazepam groups. The mean RASS change at 24 hours was -2.3 for the haloperidol alone group, -4.5 for the lorazepam group, -4.3 for the combination group, and -2.8 for the placebo group. Compared with patients in the haloperidol group, those in the lorazepam and combination group had significantly lower RASS scores, with a mean difference of about -2. The difference in RASS scores between the haloperidol and placebo groups was not significant (-0.5; 95% CI, -1.7 to 0.7), nor was the difference between the combination and lorazepam groups (0.2; 95% CI, -1.1 to 1.4). The combination and lorazepam groups needed significantly fewer rescue medications for breakthrough restlessness or agitation (32% and 37%, respectively) than the haloperidol and placebo groups (56% and 83%, respectively). Hiu and colleagues also noted no differences in survival or adverse events between the groups. 'Taken together, these study findings highlight three options with light (haloperidol), moderate (lorazepam), and heavy (combination) sedation for persistent restlessness and agitation in the end-of-life setting,' the authors wrote. Perspectives: Striking a Balance Thomas B. Strouse, MD, who was not involved in the study, explained that overall 'most practitioners would agree that combining a sedative-hypnotic like lorazepam or midazolam with an antipsychotic like haloperidol or olanzapine are reasonable strategies' for treating agitated delirium in the last days of life for someone with advanced cancer. Strouse, David Geffen School of Medicine, UCLA, explained that he and many colleagues often use antipsychotic agents other than haloperidol, such as olanzapine or quetiapine, which he said are more sedating with generally fewer side effects, particularly akathisia or motor restlessness that 'can sometimes be hard to distinguish from the agitated delirium one is trying to reduce.' In an invited commentary, palliative care experts Justin J. Sanders, MD, MSc, and James Downar, MDCM, MHSc, highlighted important questions raised by the trial. Notably, the goal of managing agitated delirium is not typically about lowering RASS as much as possible but rather about achieving a mid-range of 0 to -2 where patients are calm but not over-sedated. However, most patients in the lorazepam groups achieved a mean RASS score below that target, meaning these patients were more heavily sedated, Sanders, of McGill University, Montreal, Quebec, Canada, and Downar, of the University of Ottawa, Ottawa, Ontario, Canada, explained. When managing delirium, there is often a trade-off between managing the agitated delirium and keeping patients aware and conscious enough to continue communicating, Sanders explained in an interview with Medscape Medical News . Sanders discusses this trade-off with patients and families, telling them that 'we have medications that can treat the delirium, but it will come at the expense of alertness.' He then works with families to help make the best decisions based on their values. Overall, Sanders called this study 'an extraordinary trial in our field,' citing its level of complexity, including the contributions from patients and families. In a comment reacting to the study, Hiroyuki Otani, MD, of Kyushu Cancer Center in Fukuoka, Japan, agreed and elaborated on ambiguity of these end-of-life decisions. 'Deep sedation occupies a complex emotional and ethical space,' Otani wrote. 'While it may relieve visible distress, it may also preclude final opportunities for expression — a glance, a whispered farewell, a final touch.' The trial, Otani concluded, 'calls us to reimagine sedation not merely as symptom control but as a final act of care — where relief, reverence, and relational presence converge at the threshold of life's end.'
Yahoo
06-08-2025
- Yahoo
Glasgow hospice funding plea as it reveals £755k shortfall
A GLASGOW hospice has begun a fundraising campaign after revealing it faces a shortfall of more than three quarters of a million pounds. The Prince and Princess of Wales Hospice in Bellahouston Park is hoping 'the local community' will support its Vital Care Appeal. Chief Executive Rhona Baillie said: 'We provide free specialist palliative and end-of-life care to 1200 new patients and their families each year, both at the hospice at Bellahouston Park and in patients' own homes. 'We're doing everything we can to keep our costs to a minimum. We run our services efficiently, we're innovating with our fundraising, and we make every pound count. 'But despite our efforts, a significant funding gap remains.' (Image: Colin Mearns/Newsquest) The hospice is predicting a £755,000 shortfall in funding, citing the rise in demand for its services, patients' more complex needs and rising costs as the main pressures. Ms Baillie said that 'with local government funding just 30 per cent of running the hospice, the remaining 70 per cent comes from fundraising and donations' and added: 'We're not in crisis yet, but we need to act and that's why we are turning to our friends in the community for help.' Kirsty with her dad, Robert (Image: PPWH) Kirsty Dolan, 22, is supporting the appeal following the death of her dad, Robert, in the hospice in 2021. Robert was diagnosed with Parkinson's when he was 48 and Kirsty, who was only 10 at the time, along with her mum and older sister, became carers for him. In 2021, he visited the hospital for inpatient care. READ NEXT: Seeds of trees which survived Hiroshima help create new Glasgow garden Glasgow pupil heading for top art school after exam success 'We'll use King's Honours to keep battling for our Glasgow community' 'He had developed supranuclear palsy and needed specialist care,' said Kirsty. 'He was in the IPU for about a week where he just received the very best care you could imagine. 'We got to spend as much time with him as we could, and we even got to bring our dogs in for a visit. When he was nearing the end of his life, we all stayed over at the hospice in the family rooms so we could be close.' Kirsty also received support from the hospice's Family Support Service. 'I was really struggling,' she said. 'I was at breaking point. I emailed the hospice and the Family Support Service got in touch – and I have to say, it changed my life. "The team worked with me over a period of time and just helped me see things differently. ' It really was a lifeline, and I needed that support so much.' Glasgow Times readers helped raise the £21m needed for the new hospice, which opened in 2018, through our Brick by Brick Appeal. For more information on the Vital Care Appeal visit or call 0141 726 2660.
Yahoo
04-08-2025
- Yahoo
Terminally ill south Essex patient 'died at home alone after discharge from hospital'
A TERMINALLY ill woman, who was discharged from hospital, died alone in her home and lay undiscovered for days, a councillor has revealed. Thurrock Councillor Cici Manwa, Labour councillor for Tilbury Riverside and Thurrock Park, spoke out at a meeting of Thurrock Council's adult and health services overview and scrutiny committee. Kevin Garod, anchor programme manager at Mid and South Essex NHS Foundation Trust. attended the meeting on Thursday to outline the trust's healthcare strategy over the next ten years. It involves more care in the community to alleviate pressure on hospitals. After listening to the strategy, Ms Manwa said: 'Recently I had a bereavement of a family friend of mine. She lived in Tilbury and she was terminally ill with cancer. 'She was in the hospital for quite some time and she came out and she was at home alone. There wasn't really any support or aftercare from when she left the hospital and she ended up dying alone. People didn't even know she was dead until a few days later.' Read more Plans submitted for 22-bed cutting-edge kidney centre at Basildon Hospital More than £11,800 raised to help fund new equipment at Basildon Hospital Building work forces temporary closure of south Essex blood testing clinic Essex man who 'died for ten minutes' to visit blood donor centre and thank staff Ms Manwa added: 'Considering she was somebody who spent her whole life working in Grays in palliative care, helping other people, the manner in which she died was very tragic. 'We're looking at a ten-year plan, but right now it seems as though services don't seem particularly joined up. I'm specifically talking about terminally ill people. People with cancer. They're coming to the end of their life but that dignity should be expected throughout their entire lifetime. I hope that nobody else in Thurrock will have to experience what she had to go through.' Last year, Healthwatch Thurrock published a report on discharges from the three Mid and South Essex NHS Trust (MSE) hospitals at Basildon, Southend and Broomfield. While discharges are handled by hospitals, social workers and NHS staff in communities, the report said there had been an increased number of 'failed' and unsafe discharges' because it is believed some patients are being discharged too soon. Mark Hooper, councillor responsible for health and wellbeing, confirmed the incident wasn't an isolated one. He said: 'I thank councillor Manwa and recently councillor Fox who raised issues around discharge from Southend Hospital to Thurrock. 'Maybe we could have a meeting to look at this because there are number of concerns round discharge from Southend back to Thurrock. This is about the fifth case I've heard in about six months.'
